RedHill Biopharma
在场
RedHill Biopharma 是一家在股票代码 RDHL (IL) 下上市的公司。
高管
查看带有其 18 名主要高管的组织结构图
RedHill Biopharma 搜索最多的简介
- Dror Ben-Asher, Chief Executive Officer and Chairman of the Board
- Eric Swenden, Director
- Shmuel Cabilly, Director
创建提醒
跟踪 RedHill Biopharma 的高管变动
药店
RedHill Biopharma 拥有 1,832 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- Jazz Pharmaceuticals 已收购 Chimerix (公布2025三月6号).
- Cosette Pharmaceuticals has announced the acquisition of Mayne Pharma (公布2025二月25号).
- Bain Capital 已收购 Mitsubishi Tanabe Pharma (公布2025二月12号).
药店 行业的其他推荐联系人
消息
RedHill Biopharma 的最新新闻稿
- RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
- RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
- RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
- RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
- Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
- RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
- RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
- RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
- RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
- RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
- View more press releases Close
